Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nebivolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | NPY1R | P25929 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nebivolol SCHEMBL18255259 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL13762675 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL20007010 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL12375910 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL7919700 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL8511892 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL3909519 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL8503436 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL3791946 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR | |
| Nebivolol SCHEMBL2837419 | 1.00 | HTR1A (1.00) | HTR1ADRD2HTR2AHTR2CMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220333169-A1 | Polygenic Score for Cardiac Heart Failure | HENRY FORD HEALTH SYSTEM (US) | 2022-10-20 | — | — | US | claimed |
| WO-2022159852-A1 | METHODS AND COMPOSITIONS FOR TREATING ADENOID CYSTIC CARCINOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-07-28 | — | — | WO | claimed |
| US-20210198741-A1 | IDENTIFICATION OF SPATIAL BIOMARKERS OF HEART DISORDERS AND METHODS OF USING THE SAME | 10X GENOMICS, INC. | 2021-07-01 | — | — | US | claimed |
| WO-2021051033-A1 | POLYGENIC SCORE FOR CARDIAC HEART FAILURE | HENRY FORD HEALTH SYSTEM (US) | 2021-03-18 | — | — | WO | claimed |
| US-20170304388-A1 | NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12622971-B2 | Linear polysaccharide based film products | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12625124-B2 | Methods for validating medication | VALISURE LLC (US) | 2026-05-12 | — | — | US | disclosed |
| WO-2026085560-A1 | METHODS AND AGENTS FOR TREATING BLOOD FLOW DISORDERS | Implicit Bioscience Limited (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | NOVARTIS PHARMA AG (CH) | 2026-04-23 | — | — | US | disclosed |
| US-20260098246-A1 | COMPOSITIONS AND PROCESSES FOR ENGINEERING URETERIC BUD KIDNEY TISSUES AND IN-VITRO COMPOSITIONS THEREOF | TRESTLE BIOTHERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-1737847-A2 | NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | Torrent Pharmaceuticals Ltd (IN) | 2007-01-03 | — | — | EP | disclosed |
| US-7138430-B2 | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use | NITROMED, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| WO-2006025070-A2 | NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-03-09 | — | — | WO | disclosed |
| US-20060009513-A1 | Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| CN-1683355-A | Process for preparing DL-nebivolol and its hydrochloride | XINCHANG PHARMACEUTICAL FACTORY ZHEJIANG MEDICINE CO LTD (CN) | 2005-10-19 | — | — | CN | disclosed |
| US-20040132805-A1 | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use | NITROMED, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20030099636-A1 | Curing method for pathologic syndrome and medicinal preparation | EPSHTEIN, OLEG I. (RU) | 2003-05-29 | — | — | US | disclosed |
| EP-1295606-A1 | CURING METHOD FOR PATHOLOGIC SYNDROME AND A MEDICINAL PREPARATION | Epshtein, Oleg Iliich (RU) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132805-A1 | Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use | ADRB1, NOS2, NOS1 | ADRB2 4/4885ADRB1 1/4885HTR1A 2638/4885 |
| US-20260108490-A1 | TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER | PMP22, PSMB2, SMN1; SMN2 | ADRB2 43/4885ADRB1 214/4885HTR1A 3283/4885 |
| US-20260098246-A1 | COMPOSITIONS AND PROCESSES FOR ENGINEERING URETERIC BUD KIDNEY TISSUES AND IN-VITRO COMPOSITIONS THEREOF | PAX2, PAX3, PAXBP1 | ADRB2 2721/4885ADRB1 2697/4885HTR1A 3659/4885 |
| US-12625124-B2 | Methods for validating medication | SRMS, CYP2C19, CYP2C9 | ADRB2 135/4885ADRB1 424/4885HTR1A 452/4885 |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | HTR6, HTR2A, OPRL1 | ADRB2 862/4885ADRB1 464/4885HTR1A 4/4885 |
| US-20060009513-A1 | Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use | NOS1, ADRB1, NOS2 | ADRB2 4/4885ADRB1 2/4885HTR1A 2805/4885 |
| US-12622971-B2 | Linear polysaccharide based film products | SORD, SMCHD1, PLEC | ADRB2 1592/4885ADRB1 2249/4885HTR1A 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.